Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression
Advanced Science · 2026
DOI: 10.1002/advs.202507008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Siyu Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Bufanolides, Breast Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project-Clinical Chinese Pharmacy, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Breast cancer incidence is rising globally, presenting challenges such as treatment side effects and drug resistance. Bufalin is a bufadienolides compound with potential anti‐cancer effects. This study shows that bufalin inhibits malignant proliferation of MDA‐MB‐231 and MCF‐7 cells and protects mice against breast cancer. Of note, GTF3C4 was identified as the target protein by Limited Proteolysis‐Mass Spectrometry. GTF3C4 is overexpressed in breast cancer and associated with poor prognosis. RNA sequencing analysis reveals that the PI3K/AKT signaling pathway is a key contributor. Using cell thermal shift assays, drug affinity response target stability assays, and surface plasmon resonance, it was verified that bufalin can specifically bind to GTF3C4. Bufalin reduces GTF3C4 protein levels in vivo and in vitro, effectively inhibiting breast cancer progression by suppressing the PI3K/AKT signaling pathway. After the knockdown of GTF3C4, the PI3K/AKT signaling pathway is also suppressed, thereby inhibiting the proliferation of breast cancer cells and promoting apoptosis. Single‐cell RNA sequencing results indicated that bufalin reduces the proportions of macrophages, neutrophils, and monocytes, and affects the strength of receptor‐ligand signals between cells. Collectively, this study demonstrates that bufalin targets GTF3C4 to inhibit the PI3K/AKT pathway and remodels the tumor microenvironment, thereby hindering the malignant progression of breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
- Modern Research Center For Traditional Chinese Medicine, Beijing Institute of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
- Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
ORCID-Profile: Jiarui Wu
Förderung
- Beijing Natural Science Foundation
- State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project-Clinical Chinese Pharmacy
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Guo, S., Chen, X., Wang, H., Zhou, J., Lu, P., Liu, J., Chai, K., Zhang, J., Yang, S., Lu, S., Gao, Y., Jin, Z., Tao, X., Hu, Z., Li, Q., & Wu, J. (2026). Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression. Advanced Science. https://doi.org/10.1002/advs.202507008
Vancouver
Guo S, Chen X, Wang H, Zhou J, Lu P, Liu J, et al. Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression. Advanced Science. 2026. doi:10.1002/advs.202507008
BibTeX
@article{Guo2026,
author = {Guo, Siyu and Chen, Xiaodong and Wang, Haojia and Zhou, Jiying and Lu, Peiying and Liu, Jiangying and Chai, Keyan and Zhang, Jingyuan and Yang, Siyun and Lu, Shan and Gao, Yifei and Jin, Zhengsen and Tao, Xiaoyu and Hu, Zhongdong and Li, Qinglin and Wu, Jiarui},
title = {Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202507008}
}
EUVIMED